https://www.selleckchem.com/products/foxy5.html
001). Among gout patients, those receiving ULT excluding probenecid (aHR = 0.80; 95%CI = 0.64-1.0, all had significantly lower risk of T2DM than gout patients without ULT (all aHR less then 0.90; all P less then 0.001). In this study, we found that gout increased the risk of T2DM; however, patients with any ULT exhibited a lower risk of T2DM than gout patients without any ULT (all aHR less then 0.90, P less then 0.001; excluding probenecid). Type 2 diabetic (T2D) male patients with low total testosterone (TT) levels are at an increasing
Like
Comment
Share
